Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study

BACKGROUND: Tenofovir disoproxil fumarate (TDF) is widely used and recommended as first-line treatment for patients infected with the hepatitis B virus (HBV). However, current data are limited regarding the efficacy and safety of switching to TDF for the treatment of chronic hepatitis B in hepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Fumitaka, Suzuki, Yoshiyuki, Karino, Yoshiyasu, Tanaka, Yasuhito, Kurosaki, Masayuki, Yatsuhashi, Hiroshi, Atarashi, Tomofumi, Atsukawa, Masanori, Watanabe, Tsunamasa, Enomoto, Masaru, Kudo, Masatoshi, Maeda, Naoto, Kohno, Hiroshi, Joko, Kouji, Michitaka, Kojiro, Miki, Koichiro, Takahashi, Kazuhiro, Ide, Tatsuya, Fujiyama, Shigetoshi, Kohno, Tomoko, Itoh, Hiroshi, Tsukamoto, Sakiyo, Suzuki, Yuko, Kawano, Yoshiaki, Sugiura, Wataru, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686386/
https://www.ncbi.nlm.nih.gov/pubmed/34930140
http://dx.doi.org/10.1186/s12876-021-02008-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686386/
https://www.ncbi.nlm.nih.gov/pubmed/34930140
http://dx.doi.org/10.1186/s12876-021-02008-9

Ejemplares similares